Statin use and survival in colorectal cancer: Results from a population-based cohort study and an updated systematic review and meta-analysis

Cancer Epidemiology

Volumn 45, Issue , 2016, Pages 71-81

  Gray, Ronan T ^a   Coleman, Helen G ^a   Hughes, Carmel ^a   Murray, Liam J ^a   Cardwell, Chris R ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Colorectal neoplasms; Hydroxymethylglutaryl CoA reductase inhibitors; Meta analysis; Pharmacoepidemiology; Review; Survival; Systematic

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; CELL HETEROGENEITY; COHORT ANALYSIS; COLORECTAL CANCER; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; HAZARD RATIO; HUMAN; META ANALYSIS; POPULATION MODEL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUALITY CONTROL; QUANTITATIVE STUDY; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; COLORECTAL NEOPLASMS; MORTALITY; PROGNOSIS; SCOTLAND; SURVIVAL RATE;

COHORT STUDIES; COLORECTAL NEOPLASMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROGNOSIS; SCOTLAND; SURVIVAL RATE;

EID: 84991644019     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2016.10.004     Document Type: Article

References (50)

1. J. Ferlay, I. Soerjomataram, M. Ervik, M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. (2013). Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx? (accessed 10.01.15).
2. Cancer Research UK. Bowel cancer Key Stats. Available at: http://publications.cancerresearchuk.org/cancerstats/statsbowel/keyfactsbowel.html. (accessed 21.01.15).
3. Coleman, M., Forman, D., Bryant, H., et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377:9760 (2011), 127–138.
4. Andre, T., Boni, C., Mounedji-Boudiaf, L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350:23 (2004), 2343–2351.
5. Gustavsson, B., Carlsson, G., Machover, D., et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin. Colorectal Cancer 14:1 (2015), 1–10.
6. Domingo, E., Church, D.N., Sieber, O., et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J. Clin. Oncol. 31:34 (2013), 4297–4305.
7. Li, P., Wu, H., Zhang, H., et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut 64:9 (2015), 1419–1425.
8. Nielsen, S.F., Nordestgaard, B.G., Bojesen, S.E., Statin use and reduced cancer-related mortality. N. Engl. J. Med. 367:19 (2012), 1792–1802.
9. Bardou, M., Barkun, A., Martel, M., Effect of statin therapy on colorectal cancer. Gut 59:11 (2010), 1572–1585.
10. Cardwell, C.R., Hicks, B.M., Hughes, C., Murray, L.J., Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J. Clin. Oncol. 32:28 (2014), 3177–3183.
11. Hoffmeister, M., Jansen, L., Rudolph, A., et al. Statin use and survival after colorectal cancer: the importance of comprehensive confounder adjustment. J. Natl. Cancer Inst., 107(6), 2015, djv045.
12. Krens, L.L., Simkens, L.H.J., Baas, J.M., et al. Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study. PLoS One, 9(11), 2014, e112201, 10.1371/journal.pone.0112201.
13. Lakha, F., Theodoratou, E., Farrington, S.M., et al. Statin use and association with colorectal cancer survival and risk: case control study with prescription data linkage. BMC Cancer, 12, 2012, 487, 10.1186/1471-2407-12-487.
14. Mace, A.G., Gantt, G.A., Skacel, M., Pai, R., Hammel, J.P., Kalady, M.F., Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer. Dis. Colon Rectum. 56:11 (2013), 1217–1227.
15. Ng, K., Ogino, S., Meyerhardt, J.A., et al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J. Natl. Cancer Inst. 103:20 (2011), 1540–1551.
16. Shao, Y.Y., Hsu, C.H., Yeh, K.H., et al. Statin use is associated with improved prognosis of colorectal cancer in Taiwan. Clin. Colorectal Cancer 14:3 (2015), 177–184.
17. Siddiqui, A.A., Nazario, H., Mahgoub, A., Patel, M., Cipher, D., Spechler, S.J., For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Dig. Dis. Sci. 54:6 (2009), 1307–1311.
18. Zanders, M.M.J., van Herk-Sukel, M.P.P., Vissers, P.A.J., Herings, R.M.C., Haak, H.R., van de Poll-Franse, L.V., Statin use as a moderator of metformin effect on overall survival in colorectal cancer patients with diabetes. Br. J. Cancer 113 (2015), 403–410.
19. Anderson, E., Von Eyben, R., Kozak, M., et al. Statin use as a predictor of outcome in colorectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 90:1 Suppl. 1 (2014), S395–S396.
20. Zhong, S., Zhang, X., Chen, L., Ma, T., Tang, J., Zhao, J., Statin use and mortality in cancer patients: systematic review and meta-analysis of observational studies. Cancer Treat. Rev. 41:6 (2015), 554–567.
21. Ling, Y., Yang, L., Huang, H., et al. Prognostic significance of statin use in colorectal cancer. Medicine (Baltimore), 94(25), 2015, e908, 10.1097/MD.0000000000000908.
22. Cai, H., Zhang, G., Wang, Z., Luo, Z., Zhou, X., Relationship between the use of statins and patient survival in colorectal cancer: a systematic review and meta-analysis. PLoS One, 10(6), 2015, e0126944, 10.1371/journal.pone.0126944.
23. Lévesque, L.E., Hanley, J.A., Kezouh, A., Suissa, S., Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ, 340, 2010, b5087.
24. Alvarez-Madrazo, S., McTaggart, S., Nangle, C., Nicholson, E., Bennie, M., Data resource profile: the Scottish national prescribing information system (PIS). Int. J. Epidemiol. 45:3 (2016), 714–715f.
25. Chubak, J., Boudreau, D.M., Wirtz, H.S., McKnight, B., Weiss, N.S., Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J. Natl. Cancer Inst. 105:19 (2013), 1456–1462.
26. Joint Formulary Committe, British National Formulary (Online). 2016, BMJ Group and Pharmaceutical Press, London Available at: http://www.medicinescomplete.com. (accessed 14.09.14).
27. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment, 2015. Oslo (2014). Available at: http://www.whocc.no/atc_ddd_publications/guidelines/. (accessed 9.11.15).
28. Sundararajan, V., Henderson, T., Perry, C., Muggivan, A., Quan, H., Ghali, W.A., New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J. Clin. Epidemiol. 57:12 (2004), 1288–1294.
29. The Scottish Government, Scottish Index of Multiple Deprivation : General Report., 2009, A Scottish Government National Statistics Publication Available at: http://www.gov.scot/Publications/2009/10/28104046/0. (accessed 14.09.14).
30. Zhou, Z., Rahme, E., Abrahamowicz, M., Pilote, L., Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am. J. Epidemiol. 162:10 (2005), 1016–1023.
31. Schisterman, E.F., Cole, S.R., Platt, R.W., Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 20:4 (2009), 488–495.
32. Weinberg, C.R., Toward a clearer definition of confounding. Am. J. Epidemiol. 137:1 (1993), 1–8.
33. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses. BMJ, 338, 2009, b2535.
34. Stroup, D.F., Berlin, J.A., Morton, S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283:15 (2000), 2008–2012.
35. G. Wells, B. Shea, D. O'Connell, et al., The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. (accessed 16.03.15).
36. Higgins, J., Green, S., (eds.) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011], 2011, The Cochrane Collaboration Available at: www.cochrane-handbook.org. (accessed 16.03.15).
37. Parmar, M.K., Torri, V., Stewart, L., Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med. 17:24 (1998), 2815–2834.
38. Higgins, J.P.T., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327:7414 (2003), 557–560.
39. Lim, S.H., Kim, T.W., Hong, Y.S., et al. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. Br. J. Cancer 113:10 (2015), 1421–1426.
40. Voorneveld, P., Reimers, M.S., Jacobs, R.J., et al. Statin use after diagnosis improves survival in colorectal cancer patients [abstract]. Gastroenterology, 148(4,1), 2015, S951.
41. Armstrong, D., Raissouni, S., Price Hiller, J., et al. Predictors of pathologic complete response after neoadjuvant treatment for rectal cancer: a multicenter study. Clin. Colorectal Cancer 14:4 (2015), 291–295.
42. Kim, B., Park, S.J., Hong, S.P., Cheon, J.H., Kim, W.H., Kim, T., Il: The effect of prediagnostic aspirin use on the prognosis of stage III colorectal cancer. Int. J. Clin. Exp. Med. 8:8 (2015), 13435–13445.
43. National Services Division. Scottish Bowel Screening Programme. Available at: http://www.nsd.scot.nhs.uk/services/Screening/bowelscreening/index.html. (accessed 21.01.16).
44. National Institute for Health and Care Excellence. Capecitabine and Oxaliplatin in the Adjuvant Treatment of Stage III (Dukes’ C) Colon Cancer (TA100). Available at: https://www.nice.org.uk/guidance/ta100/chapter/About-this-guidance. (accessed 21.01.16).
45. Lee, J.E., Baba, Y., Ng, K., et al. Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev. Res. 4:11 (2011), 1808–1815.
46. Freed-Pastor, W.A., Mizuno, H., Zhao, X., et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148:1–2 (2012), 244–258.
47. Bengtsson, E., Nerjovaj, P., Wangefjord, S., et al. HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome. Diagn. Pathol., 9, 2014, 78, 10.1186/1746-1596-9-7.
48. Ahern, T.P., Lash, T.L., Damkier, P., Christiansen, P.M., Cronin-Fenton, D.P., Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol. 15:10 (2014), e461–8.
49. Shrank, W.H., Patrick, A.R., Brookhart, M.A., Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J. Gen. Intern. Med. 26:5 (2011), 546–550.
50. National Surgical Adjuvant Breast and Bowel Project Foundation. Statin Polyp Prevention Trial in Patients with Resected Colon Cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT01011478. (accessed 02.12.15).